Hemab Therapeutics Hldgs (COAG) closed at $38.50 on October 28, 2026, up 0.3% from the previous close, on volume of 404,623 shares (30-day average 526,903).
Data as of October 28, 2026.
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Globe Newswire (Thu, 24-Sep 4:01 PM ET)
COAG advances HMB-003 into Phase 1 with once-per-cycle dosing potential for heavy menstrual bleeding
Market Chameleon (Fri, 18-Sep 6:56 AM ET)
Globe Newswire (Thu, 17-Sep 8:00 AM ET)
/C O R R E C T I O N -- The Galien Foundation/
PRNewswire (Mon, 17-Aug 4:15 AM ET)
PRNewswire (Thu, 13-Aug 9:00 AM ET)
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 11-Aug 7:00 AM ET)
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Hemab Therapeutics Hldgs trades on the NASDAQ stock market under the symbol COAG.
As of October 29, 2026, COAG stock price climbed to $41.24 with 587,895 million shares trading.
COAG has a beta of -0.67, meaning it tends to be less sensitive to market movements. COAG has a correlation of 0.01 to the broad based SPY ETF.
COAG has a market cap of $1.93 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that COAG belongs to (by Net Assets): XBI, IWM, VTI, VXF, IWO.
COAG support price is $36.51 and resistance is $40.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COAG shares will trade within this expected range on the day.
